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Donated chemical probes for
open science
Abstract Potent, selective and broadly characterized small molecule modulators of protein function (chemical
probes) are powerful research reagents. The pharmaceutical industry has generated many high-quality chemical
probes and several of these have been made available to academia. However, probe-associated data and control
compounds, such as inactive structurally related molecules and their associated data, are generally not accessible.
The lack of data and guidance makes it difficult for researchers to decide which chemical tools to choose. Several
pharmaceutical companies (AbbVie, Bayer, Boehringer Ingelheim, Janssen, MSD, Pfizer, and Takeda) have
therefore entered into a pre-competitive collaboration to make available a large number of innovative high-quality
probes, including all probe-associated data, control compounds and recommendations on use (https://
openscienceprobes.sgc-frankfurt.de/). Here we describe the chemical tools and target-related knowledge that
have been made available, and encourage others to join the project.
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“Man must shape his tools lest
they shape him” (Arthur Miller)
The function of a protein can be explored in sev-
eral different ways. Genetic approaches are
used to suppress the expression of the respec-
tive gene/protein, for example using gene edit-
ing methods such as siRNA or shRNA or by
CRISPR/Cas9 (Mali et al., 2013). However, in
drug discovery, these methods have some defi-
ciencies: they commonly remove or suppress the
entire protein and thus cannot easily reveal the
function of a specific druggable protein domain
– although domain-based CRISPR is becoming a
more widely used method; they are not
reversible; their effects are not instantaneous;
and they not only disrupt the protein, but also
the protein interactome around the targeted
protein. Selective small molecule modulators
(‘chemical probes’), in contrast, can probe the
particular function of a targeted domain and
can, therefore, be used to study its role in bio-
logical processes and in human disease in a
dose and time-dependent manner across a wide
range of cell and animal models. These probes
can also be modified to enhance the degrada-
tion of the protein(s) they bind to (Mali et al.,
2013; Toure and Crews, 2016).
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Small molecules can be used in a broad panel
of assay systems comprising primary cells, tis-
sues and also in vivo models, and other systems
not easily amenable even for state-of-the-art
genetic target validation methods. Despite the
fact that non-selective compounds cast a wide
net and can be used to uncover interesting poly-
pharmacologies, having a panel of selective
probes that can be used in combination will
facilitate data deconvolution and target identifi-
cation. These properties, together with the pos-
sibility of further development of probes into
drug candidates, make them among the most
versatile tools to explore the relevance of a pro-
tein for therapeutic development. However, the
necessary characterization data is often missing
for chemical compounds, and inhibitors are
announced as being ‘selective’ despite missing a
comprehensive profile. Tool compounds, which
are chemically unstable or not comprehensively
characterized are therefore limited in their utility
(Arrowsmith et al., 2015). Moreover, poorly
characterized chemical modulators generate
misleading results and litter the literature with
contradicting data on a target’s function and its
role in biology. This is also true for probes that
are used improperly, e.g. at higher than appro-
priate concentration thus inhibiting other pro-
teins in addition to the target or resulting in
non-specific cellular toxicity. Unfortunately,
reactive and non-specific inhibitors are widely
used in the academic research community, often
resulting in incorrect functional annotation
(Baell and Walters, 2014).
The ideal chemical probes need to be selec-
tive, active in cells and chemically stable. The
recent discussion on best practice within the
chemical biology community suggested a num-
ber of stringent quality criteria for chemical
probes (Arrowsmith et al., 2015; Blagg and
Workman, 2017; Edwards et al., 2009;
Bunnage et al., 2013). Typical criteria as applied
by the Structural Genomics Consortium (SGC)
are shown in Figure 1, although these may vary
slightly depending on the specific protein.
A diverse set of chemical tool compounds is
available to cell biologists. However, characteri-
zation data associated with these compounds
are often either incomplete or buried in patents
or supplemental data files of publications. Thus,
scientists face a challenge to decide which tools
to use for their research. Help is provided for
example by the Chemical Probes Portal
(Baell and Walters, 2014; Blagg and Workman,
2017), which was established in 2015 to provide
a comprehensive overview of published and
newly released tool compounds that are anno-
tated with a simple star-rating system. All com-
pounds submitted to the portal are reviewed by
at least three members of an independent
Figure 1. Chemical probes need to fulfil stringent criteria to qualify as research tools. Shown here are target and
compound related criteria applied by the Structural Genomics Consortium.
DOI: https://doi.org/10.7554/eLife.34311.002
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expert scientific advisory board. Only probes
that receive three stars (‘Best available probe for
this target, or a high-quality probe that is a use-
ful orthogonal tool’) or four
stars (‘Recommended as a probe for this target’)
are recommended to be used. Of all the com-
pounds submitted to the probe portal so far
(about 400), 125 have achieved a rating of three
stars or better, thereby showing that there is an
urgent need for more high-quality tool com-
pounds to foster reproducible research.
“Excellence, then, is not an act,
but a habit” (Will Durant
[Durant, 1926])
Like drug discovery, probe development is a
multi-disciplinary effort involving experts from
several areas including protein chemistry, bio-
chemistry, cell biology, pharmacology and
medicinal chemistry (Dahlin and Walters, 2014;
Garbaccio and Parmee, 2016). Once a target
has been selected, the first step is the design of
a project-specific screening cascade. The screen-
ing procedure needs to reflect target-related
probe criteria as well as the desired compound
properties.
A typical screening cascade for a kinase
probe discovery project is shown in Figure 2.
The screening cascade consists of a primary
assay – usually a biochemical activity assay – plus
an assay with an orthogonal readout, e.g., a
biophysical assay, a number of selectivity assays
for the target and a cell-based assay to demon-
strate on-target activity in the cellular environ-
ment. If possible, a crystallization system should
be established to elucidate the binding modes
of selected compounds enabling the rational
design of better inhibitors. In silico analyses to
exclude undesired events such as frequent hit-
ters and pan-assay interference compounds
(PAINs), and assays characterizing the physical
and chemical properties of the identified hits
(Hughes et al., 2011) complement the analysis
(Baell and Walters, 2014). Medicinal chemistry
optimization is then started for selected com-
pound classes. For a typical project, multiple
rounds of the Design – Make – Test – Analyze
circle (Plowright et al., 2012) are needed
before a suitable probe candidate is identified.
Importantly, cross-correlating results from differ-
ent assays within a compound class (e.g. tracking
of cellular read-outs with biochemical potency
and cellular target engagement data) provide a
continuing consistency check if observed effects
are truly a function of inhibiting the target of
interest. Experience within the SGC shows that
approximately 1–2 years and e2 million are
needed to generate one chemical probe fulfilling
these stringent criteria (Donner, 2014). This
observation is in line with the experience of
many medicinal chemists at pharmaceutical
companies.
Figure 2. Typical workflow for a kinase probe discovery project. Medicinal chemistry optimization involving
multiple iterative steps of compound design, synthesis and screening are necessary until probe criteria are
fulfilled.
DOI: https://doi.org/10.7554/eLife.34311.003
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As there may be similarities among binding
sites on both related and unrelated proteins,
unwanted binding to proteins other than the
original target is regularly observed. This selec-
tivity challenge can never be completely
avoided, and thus the end users should be
aware of unknown cross-reactivity challenges. A
way to reduce the risk of non-specific effects is
the use of a suitable control compound having a
chemical structure closely related to that of the
probe but lacking activity on the target. A wider
profiling against a panel of pharmacologically
active targets or proteomics analysis of the com-
pound provides additional information about
compound selectivity. Having access to multiple
probes from structurally different chemical series
further reduces the risk that unknown off-target
activities give rise to incorrect conclusions about
target functions.
“Well begun is half done”
(Aristotle)
Many quality probe compounds are buried in
the chemical vaults of the pharmaceutical indus-
try, depriving the scientific community of useful
tools and limiting the impact of the original
research. In some cases, particular compounds,
their properties and some structure–activity rela-
tionships (SAR) have been published
(Nara et al., 2014; Siebeneicher et al., 2016;
Takahashi et al., 2015; Wu-Wong et al., 1999).
However, often only selected data are published
and the proprietary compounds are not made
available to the researchers except via restrictive
contractual agreements, and this impedes their
use and their impact. Indeed, in the nuclear hor-
mone receptor field, we showed that any legal
encumbrances to compound access reduced the
subsequent use of the compound in the litera-
ture significantly (Isserlin, 2011). Thus, the open
access/open science approach is the fastest
route to reach the end users and thereby to
have a positive effect on research.
This evidence, as well as impact from the
SGC epigenetics probes project, has convinced
the SGC partner companies that the release of
previously hidden compounds and data to the
public will provide value to science and to the
companies (Lee, 2015). To this end, seven phar-
maceutical companies associated with the SGC
have each agreed to donate 10 of these valuable
compounds, stemming from their research pipe-
lines, for a total of 70 high-quality small mole-
cules, thus providing a major boost to the
chemical biology toolbox. The compounds have
been selected based on a variety of criteria,
which are different for each participating com-
pany. These include profiling available for the
compound, feasibility of generating a control
compound, availability of physical compound,
target class, intellectual property considerations,
and other factors.
This is an exciting development, but many of
the compounds will require wider profiling to
meet today’s more stringent quality criteria. As
the primary focus of the pharmaceutical industry
is not to generate chemical probes, but to
develop new drugs, not all donated probes have
been profiled to the same depth that is required
of a high-quality chemical probe. Moreover,
specificity for a particular target is not a require-
ment for an effective drug. Thus, although most
of the pharma-donated probes have been exten-
sively characterized, they often need to be bet-
ter adapted for use as a single chemical tool
(Figure 1). In particular, no bespoke control
compounds have been generated as the prog-
ress of the probe compounds within the com-
pany is usually followed by extensive SAR across
a series of analogues. Selection and characteri-
zation of the control compound is needed to
complete a probe package. In addition, control
compounds also have to be carefully character-
ized to weed out promiscuous compounds.
The aim of our partnership is to provide this
comprehensive characterization. We believe this
to be a valuable contribution to the community.
Once broadly characterized and accompanied
by relevant control compounds, the initial set of
70 probes reflect a collective contribution of at
least e140 million to the public domain (Fig-
ure 3). These donated probes cover a broad
array of targets from different protein families
relevant for a number of disease indications (see
Table 1).
In order to guarantee the quality of the com-
pounds, the donated probe candidates and con-
trol compounds are subjected to a two-tier
scientific review process: the first review takes
place internally, including partners who have not
been involved in the probe project, and the sec-
ond review is performed by a panel of renowned
scientists, who have agreed to act as indepen-
dent reviewers. The first 30 proposals were pre-
sented to the internal review committee during
a two-day meeting in June 2017 in Frankfurt am
Main, Germany, where a process for their
release to the public was also established. At
this ‘historic’ meeting scientists from eight phar-
maceutical companies scrutinized the quality of
the probes proposed by the other partners and
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made constructive suggestions on improvement
of the associated data packages (Figure 4A).
In the initial set, most targets are uniquely
addressed by only one chemical compound, but
a maximum of two chemical probes for the same
target will be accepted if they represent differ-
ent chemotypes as judged by the review panels.
The remaining probe sets will be provided dur-
ing the course of 2018/2019. All approved
probes are measured against the same quality
criteria (Figure 1) and will be profiled in assay
panels comprising of >500 assays, including
broad panels of pharmacologically active targets
such as GPCRs, kinases, ion channels and pro-
teases to identify off-target activities (Table 2).
Disease-specific phenotypic panels such as
assays in primary tissues established by SGC
partners will provide an initial characterization of
their biological effects (Edwards et al., 2015).
The proposed probes range from completely
novel ‘best in class’, to probes that have been
selected because they are provided as a com-
plete set, with control compounds. Although
some of the proposed compounds themselves
are already commercially available, for most
there is no widely characterized partner control
compound (Figure 4B).
The current probe proposals cover proteins
from many different families such as GPCRs, kin-
ases and proteases as well as other protein tar-
gets implicated in a variety of therapeutic areas
ranging from oncology to inflammatory diseases
and neurodegenerative disorders. An excellent
example of a donated probe is the recently pub-
lished p300/CBP histone acetyltransferase (HAT)
inhibitor (A-485), which was shown to have effi-
cacy in several cell models of malignancies
(Lasko et al., 2017). This probe, including its
control compound, has been approved by both
internal as well as external reviewers and is now
available to the scientific community. In contrast,
other donated probes are not published or only
mentioned in patents and therefore have not
been accessible at all. Examples include a novel
coagulation factor II thrombin receptor (F2R/
PAR-1) inhibitor, which has potential for throm-
bosis management, and an inhibitor for focal
adhesion kinase (FAK) and proline-rich tyrosine
kinase 2 (PYK2), which has been in clinical trials
for advanced non-haematologic malignancies,
but for which profiling data have not yet been
available. Even previously published probes are
not always widely accessible. For example, the
set includes a probe for the solute carrier NHE1,
a target associated with ischemia/reperfusion-
Figure 3. Overview of targets for which pharmaceutical companies have volunteered to donate chemical
probes. Planned release for wave one probes is in spring 2018 pending the outcome of independent peer
review. The targets of this first wave of probes are given in Table 1. Final numbers may slightly vary as some
chemical probes are still in the approval process.
DOI: https://doi.org/10.7554/eLife.34311.004
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Table 1. Targets of first wave of donated probes (approved or close to approval).
Family Target
Mode of
action Company Structure
D4 Dopamine receptor Agonist AbbVie
ABT-724
GPCR ETA Endothelin receptor Antagonist AbbVie
ABT-546
Par1/F2R (F2R) Protease activated receptor Antagonist Bayer
BAY-386
CRTH2 (Prostaglandin DP2 receptor) Antagonist MSD
CRTH2i
CB1 Cannabinoid receptor Inverse
Agonist
MSD
MRL-650
EP2Prostaglandin receptor Antagonist Pfizer
PF-04418948
a1D Adrenoceptor Antagonist Takeda
(R)-9s
KISS1 Receptor (GPR54) Agonist Takeda
KISS1-305
D-Tyr-D-Pya(4)-Asn-Ser-Phe-azaGly-
Leu-Arg(Me)-Phe-NH2
Table 1 continued on next page
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Table 1 continued
Family Target
Mode of
action Company Structure
Hydrolase sEH (Soluble epoxide hydrolase) Inhibitor Boehringer
Ingelheim
BI-1935
FAAH (Fatty acid amide hydrolase) Inhibitor Pfizer
PF-04457845
Ion
channel
TRPM8 (Cold and menthol receptor 1) Antagonist Pfizer
PF-05105679
Table 1 continued on next page
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Table 1 continued
Family Target
Mode of
action Company Structure
Kinase c-MET (Tyrosine-protein Kinase Met) Inhibitor Bayer
BAY-474
TIE (Tyrosine kinase with Ig and EGF homology domains 1), DDR
(Discoidin domain receptor family)
Inhibitor Bayer
BAY-826
ERK1/2 (Extracellular signal-regulated kinase) Inhibitor MSD
MRK-ERKi
SYK (Spleen tyrosine kinase) Inhibitor MSD
MRL-SYKi
FAK/PYK2
(focal adhesion kinase
/proline-rich tyrosine kinase 2)
Inhibitor Pfizer
PF-04554878
Table 1 continued on next page
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Table 1 continued
Family Target
Mode of
action Company Structure
Other
FLAP (5-Lipoxygenase-activating protein) Inhibitor Boehringer
Ingelheim
BI 665915
FASN (Fatty acid synthase) Inhibitor Boehringer
Ingelheim
BI 99179
MIF (Macrophage migration inhibitory factor) Activator Takeda
BTZO-1
Farnesyltransferase Inhibitor AbbVie
ABT-100
P300/CBP
(E1A binding protein/
CREB binding protein)
Inhibitor AbbVie
A-485
NHE1, SLC9A1 Antagonist Boehringer
Ingelheim
BI-9267
MTH1 (MutT homolog 1) Inhibitor Bayer
BAY-707
Table 1 continued on next page
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induced cell death, a peptidomimetic agonist for
the KISS1 receptor, which plays a crucial role in
cellular hormone function and puberty, and the
inhibitor for a gamma secretase (GSI) protease,
which may have potential in targeting Alz-
heimer’s disease.
Using the infrastructure and established pro-
cesses of past SGC probe projects, a non-
bureaucratic and simple distribution process is
implemented. This process involves distribution
in bespoke probe libraries under a simple web-
accessible Open Science Trust Agreement
(http://www.thesgc.org/click-trust) as well as
through trusted commercial vendors. To the
best of our knowledge, our initiative is unique in
enabling open access to well-validated probes
including controls generated in the pharmaceuti-
cal industry for diverse target families.
All supporting potency and selectivity data,
as well as advice for the appropriate use of the
compounds for cellular assays and – if applicable
– in vivo assays, will be easily accessible via the
public database (https://openscienceprobes.sgc-
frankfurt.de/). The launch for the first version is
planned for the beginning of 2018. The data-
base supports the data needs of both biologists
and chemists. The first version focusses on a
search for the target proteins, probes, control
compounds and recommendations on use. For
the second version, additional features such as
chemical substructure searches will be accessi-
ble. Full assay details will be provided and
reagents used will be listed so that scientists
using the probes are enabled to judge the qual-
ity of the data provided as well as to reproduce
key data in their own lab. For example, it is
important to know if a protein kinase has been
screened in a binding or activity assay, and
which ATP concentration has been used. Fur-
ther, the protein construct used to perform cer-
tain assays is of significance.
As both the probes and the negative controls
will be characterized in more than 500 assays,
we will generate more than 70,000 biological
data sets within the next 1–2 years: a rich and
easily accessible source for future analyses. By
Table 1 continued
Family Target
Mode of
action Company Structure
Protease MMP12 (Matrix metallopeptidase 12) Inhibitor Bayer
BAY-7598
Gamma secretase Inhibitor MSD
MRK-560
Gamma secretase Modulator MSD
GSM1
METAP2 (Methionine aminopeptidase-2) Inhibitor Takeda
TP-004
DOI: https://doi.org/10.7554/eLife.34311.005
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providing the data in a comprehensive way we
hope to extend our understanding of this partic-
ular mechanism or protein in a way that leads to
new therapeutic approaches.
The new tool compounds and the corre-
sponding data will help to improve the quality of
research and will deepen our understanding of
the target biology. However, comprehensive
characterization, which ideally should be consis-
tent to make data comparable and facilitate
data mining, comes at a cost, and in many cases
also requires resources for the (re-)synthesis of
the chemical probe. The biggest problem is in
the availability and characterization of the
Figure 4. Attrition rate and categories of donated probes.
DOI: https://doi.org/10.7554/eLife.34311.006A. Attrition rate of the approval process of the proposed chemical probes. B. Approved probes were categorized to show their differentiation from available chemical modulators (i) targets for which
there are currently no high-quality probes available; (ii) targets for which the donated probe promises a significant (e.g. 10-fold) benefit in potency or selectivity; (iii) cases in which the new donated probe
has similar potency/selectivity as currently available probes but an entirely different chemotype; (iv) best in class compound where none of the above points apply and where the benefit lies in the avail-
ability of the control compound and/or the data annotation.
Table 2. Overview of data generated for all donated probes.
Assays Scope Timing
Target-specific assays
(biochemical/
biophysical/ cell-based)
All chemical probes & controls Before release
(decision criteria)
Target-specific selectivity
panels
500+ kinases All chemical probes & controls After release
(annotation)
Broad specificity panel, 100+
ion
channels, GPCRs, proteases
30+ epigenetics targets
Phenotypic assays (cell lines &
primary human material)
3D structure of
protein-ligand complex
Subset Optional
Physchem parameters,
e.g. solubility
Subset
In vivo experiments Selected probes
These data will be made available through a publicly available database.
DOI: https://doi.org/10.7554/eLife.34311.007
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control compounds. Not all candidate probes
will have a suitable similar analogue that does
not inhibit/activate the target of interest. Fund-
ing will be necessary in order to fill such gaps,
but financing such a project and the resources
to synthesize and characterize compounds is no
easy task. It does not usually fit into the remit of
the major funding agencies and help is needed
by relevant translational organizations and indi-
vidual labs to support the project. Organizations
like the Division of Pre-Clinical Innovation of the
National Center for Advancing Translational Sci-
ences (NCATS; https://ncats.nih.gov/) and the
National Institute of Mental Health (NIMH) Psy-
choactive Drug Screening Program (https://
pdspdb.unc.edu/pdspWeb/) housed at the labo-
ratory of Dr Bryan Roth at UNC are generously
supporting this crucial endeavour by synthesiz-
ing negative controls and conducting probe pro-
filing experiments.
The distribution of probes will occur via com-
mercial vendors, but it is no trivial task to make
the well-characterized control compounds avail-
able to the user. Due to reduced revenues from
the control compounds, vendors are often reluc-
tant to offer these important controls. Regretta-
bly, researchers often perform experiments
without the appropriate control compound due
to cost reasons or because initial experiments
have already been performed without the con-
trol. A trial kit, which we will offer, including
both probe and control compound, and/or sets
of pre-diluted compounds may aid researchers
to perform properly controlled experiments
from the start. It is up to the combined efforts of
researchers, vendors, journal editors and refer-
ees to make use of the chemical probes in com-
bination with their available control standard
practice in biomedical research.
“From a small seed a mighty trunk
may grow” (Aeschylus)
While in the past almost all aspects of pharma-
ceutical research and development (R&D) were
seen as competitive, the thinking in the field has
shifted remarkably over the last decade. More
and more challenges in the R&D process are
seen as precompetitive, resulting in public–pri-
vate partnerships and multilateral, critical mass
consortia jointly addressing overarching issues.
Many pharmaceutical companies have initiated
open innovation projects interacting with the
academic community. A key success factor for
these endeavours is the easy access to know-
how and reagents without complicated
contractual arrangements (Nilsson and Felding,
2015; Ehrismann and Patel, 2015). We hope
that the project initiated here will entice other
companies and academics to follow suit and join
us in the quest to increase the availability of
well-validated probes meeting stringent quality
criteria for the scientific community and decide
to make some of their assets openly available.
Whilst ultimately, the success of the project will
depend on the willingness and support of the
scientific community, additional pharmaceutical
companies and funding bodies to engage, we
believe this is an exciting first step in uncovering
and delivering high–quality chemical probes to
unlock new biology and ultimately new high-
quality targets for drug discovery.
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